ASPRE试验:早产型子痫前期筛查的效果
这项前瞻性多中心研究在26 941例单胎妊娠中于孕11-13周联合母体因素、平均动脉压、子宫动脉搏动指数及血清标志物筛查子痫前期,可评估人群25 797例中早产型子痫前期180例(0.7%);风险阈值1/100时早产型子痫前期检出率76.7%,足月型为43.1%,筛查阳性率10.5%。
要点
- 孕11-13周联合筛查在风险阈值1/100时早产型子痫前期检出率为76.7%(138/180)。
- 同一筛查条件下足月型子痫前期检出率为43.1%(194/450),筛查阳性率10.5%。
- 该筛查效果与用于开发算法的约60 000例单胎妊娠研究相当。
核心结论
- ASPRE研究的筛查效果与用于开发算法的约60 000例单胎妊娠研究相当,后者在假阳性率10%时联合筛查检出76.6%的早产型子痫前期和38.3%的足月型子痫前期。
研究设计与样本
- 前瞻性多中心研究,对26 941例单胎妊娠在孕11-13周通过联合母体因素、平均动脉压、子宫动脉搏动指数、妊娠相关血浆蛋白A和胎盘生长因子的算法筛查早产型子痫前期。
- 估计早产型子痫前期风险大于1/100的合格孕妇被邀请参加双盲试验,从孕11-14周至36周每日服用阿司匹林150 mg或安慰剂。
- 排除1144例(4.2%)妊娠,包括失访或退出研究716例、流产243例、终止妊娠185例。
主要发现
- 研究人群25 797例妊娠中,早产型子痫前期180例(0.7%)、足月型子痫前期450例(1.7%)、无子痫前期25 167例(97.6%)。
- 在风险阈值1/100的联合早孕期筛查中,早产型子痫前期检出率为76.7%(138/180),足月型子痫前期检出率为43.1%(194/450)。
- 筛查阳性率为10.5%(2707/25 797),假阳性率为9.2%(2375/25 797)。
关键数值与推荐
- 早产型子痫前期筛查风险阈值为1/100。
- 阿司匹林组早产型子痫前期发生率降低62%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the performance of screening for preterm and term pre-eclampsia (PE) in the study population participating in the ASPRE (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention) trial. METHODS: This was a prospective first-trimester multicenter study on screening for preterm PE in 26 941 singleton pregnancies by means of an algorithm that combines maternal factors, mean arterial pressure, uterine artery pulsatility index and maternal serum pregnancy-associated plasma protein-A and placental growth factor at 11-13 weeks' gestation. Eligible women with an estimated risk for preterm PE of > 1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg per day) vs placebo from 11-14 until 36 weeks' gestation, which showed that, in the aspirin group, the incidence of preterm PE was reduced by 62%. In the screened population, the detection rates (DRs) and false-positive rates (FPRs) for delivery with PE < 37 and ≥ 37 weeks were estimated after adjustment for the effect of aspirin in those receiving this treatment. We excluded 1144 (4.2%) pregnancies because of loss to follow-up or study withdrawal (n = 716), miscarriage (n = 243) or termination (n = 185). RESULTS: The study population of 25 797 pregnancies included 180 (0.7%) cases of preterm PE, 450 (1.7%) of term PE and 25 167 (97.6%) without PE. In combined first-trimester screening for preterm PE with a risk cut-off of 1 in 100, the DR was 76.7% (138/180) for preterm PE and 43.1% (194/450) for term PE, at screen-positive rate of 10.5% (2707/25 797) and FPR of 9.2% (2375/25 797). CONCLUSION: The performance of screening in the ASPRE study was comparable with that of a study of approximately 60 000 singleton pregnancies used for development of the algorithm; in that study, combined screening detected 76.6% of cases of preterm PE and 38.3% of term PE at a FPR of 10%. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Rolnik DL, Wright D, Poon LCY, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017. PMID: 28741785. doi:10.1002/uog.18816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。